Lowest Price Guaranteed From USD 4,799
Published
September 2023
Slides
160
View Count
17487
Example Insights
Please scroll below for example insights
Report Description
The global mRNA manufacturing and mRNA synthesis market (for services) is estimated to be worth USD 1.95 billion in 2023. The global market is anticipated to decline at a CAGR of -1.7% during the forecast period. The decline in the market size over the next decade is likely to be the result of a dip in the demand for COVID vaccines till 2035. In the past few years, messenger ribonucleic acid (mRNA) has emerged as one of the key therapeutic modalities in the modern healthcare industry. Post the onset of the COVID-19 pandemic, mRNA therapeutics and mRNA vaccine manufacturing have garnered significant attention as they have evolved as a revolutionary novel drug class for the treatment of COVID-19, as well as several other diseases, such as oncological disorders, infectious diseases and genetic disorders. Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications. As a result, there is an evident increase in the demand for mRNA production capacity. Fundamentally, mRNA therapeutic / mRNA vaccine manufacturing is complex and cost intensive process that requires specialized expertise. Therefore, mRNA vaccine / therapeutic developers are actively exploring avenues that enable them to overcome the existing challenges. Amongst other alternatives, outsourcing to mRNA CDMO has emerged as a lucrative option for mRNA vaccine / therapeutic developers. In the foreseen future, as more of such RNA-based leads mature and move into the clinic and / or get commercialized, we anticipate the mRNA synthesis and mRNA manufacturing market to witness healthy market growth during the forecast period.
 |
 |
 |
The mRNA Synthesis and mRNA Manufacturing Market (2nd Edition), 2022-2035: Distribution by Type of Product (Drug Substances (APIs) and Drug Products (FDFs)), Application Area(s) (mRNA Vaccines and mRNA Therapeutics), Therapeutic Area(s) (Infectious Diseases, Oncological Disorders and Other Diseases) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts market report features an extensive study of the current market landscape, market size, market forecast and future opportunities associated with the players involved in the mRNA synthesis and mRNA manufacturing of research- and GMP-grade mRNAs for use in the development of therapeutics and vaccines. The market research report highlights efforts of several mRNA CDMO engaged in this rapidly emerging market segment of the pharmaceutical and biopharmaceuticals industry. Key takeaways of the mRNA manufacturing and mRNA synthesis market research report are briefly discussed below.
mRNA therapeutics and mRNA vaccines (such as COVID vaccine) have emerged as a promising alternative over conventional treatment approaches owing to their multiple benefits, including shorter development timelines, higher biological efficiency, and versatile delivery platforms at reduced toxicity levels. It is worth highlighting that these next generation mRNA therapeutics / mRNA vaccines are anticipated to become a powerful therapeutic modality for the treatment of a variety of refractory diseases, including infectious diseases, oncological disorders, metabolic disorders, cardiovascular disorders, cerebrovascular diseases and other diseases. In 2020, Food and Drug Administration (FDA) gave emergency use authorization to two mRNA vaccines - developed by Pfizer and BioNTech, Comirnaty® was the first COVID vaccine to receive authorization followed by Moderna’s Spikevax®. However, now in 2023, the COVID vaccine manufacturers have witnessed decline in their sales. In the near future, growth in the mRNA therapeutics and mRNA vaccines market will be driven by the launch of products for infectious diseases such as respiratory syncytial virus (RSV) infection and personalized cancer vaccines.
The manufacturing process of mRNA vaccines and mRNA therapeutics is fraught with several challenges as the mRNA production is complex, cost intensive and requires specialized expertise. Large scale mRNA manufacturing is associated with a number of challenges, mostly related to process development, technology transfer and maintaining purity and stability. Moreover, some of the processes associated with mRNA production, such as purification, involve the use of hazardous solvents / materials. Once manufactured, mRNA therapeutics / mRNA vaccines need to be stored in conditions that do not compromise their stability (thereby, requiring specialized facilities and cold chain transportation). Further, they also require appropriate drug delivery systems to efficiently administer the intervention (in a manner that they can avoid degradation by cellular endonucleases). It is worth highlighting that, currently, lipid nanoparticles (LNPs) are the most commonly used drug delivery systems in mRNA vaccines owing their capability to encapsulate and deliver genetic material to the target cells.
Given such technical and operational challenges associated with the GMP manufacturing of mRNA vaccines and mRNA therapeutics, innovators in the biopharmaceutical industry are increasingly relying on the mRNA CDMO / mRNA synthesis service providers. Further, the COVID-19 pandemic caused a notable surge in the outsourcing activity, with mRNA vaccine developers entering into strategic deals with contract service providers to cater to the urgent global demand.
 |
 |
 |
The mRNA synthesis and mRNA manufacturing service providers landscape features a mix of over 70 large, mid-sized and small companies, which claim to have the required expertise to offer mRNA synthesis service across different scales of operations, worldwide. Most of the (~50%) manufacturing facilities are located in Europe, followed by North America; prominent manufacturing hubs in the Europe include Germany, France, the UK, the Netherlands, Spain and Belgium. In addition to this, more than 95 mRNA synthesis kits, that contain reagents for the synthesis of research grade mRNAs, are currently available in the market.
Recent developments in this segment of the biopharmaceutical industry indicate that the mRNA synthesis service providers are upgrading their capabilities and infrastructure to accommodate the current and anticipated demand for mRNA GMP manufacturing. In August 2022, Samsung Biologics and GreenLight Biosciences announced the successful completion of the first commercial-scale engineering run for the companies’ mRNA COVID vaccine manufacturing. However, more recently the leading mRNA companies have announced setting up of in-house facilities for mRNA manufacturing. In May 2023, Moderna announced investment of USD 322 million in setting up a new mRNA manufacturing facility in Massachusetts, US. This came after March 2023 announcement from the company to set up a mRNA manufacturing facility in Kenya. Till 2022, Moderna had entered into several partnerships with mRNA CDMO to manufacture its COVID vaccine; however, with a rich pipeline of non-COVID mRNA therapeutics and vaccines, the company is now setting up its own manufacturing network. However, the company will continue to depend on the mRNA CDMO till the facilities are open for operation. Daiichi Sankyo is also setting up a facility near Tokyo to meet the production demand for its mRNA COVID vaccine, which received PMDA approval in August 2023.
However, we strongly believe that the several small to mid-sized mRNA companies will continue to depend on the mRNA CDMO network for fulfilling their clinical and commercial mRNA demand. As such, the mRNA CDMO will continue to enter into capacity expansions, driving the market growth for mRNA manufacturing and mRNA synthesis, though not at the scale necessitated by the COVID pandemic.
 |
 |
 |
The global market for mRNA synthesis and mRNA manufacturing services is estimated to be worth USD 1.95 billion in 2023. The market growth will be driven by the rising interest in R&D activities and the demand for non-COVID mRNA-based products. However, owing to the global decline in demand for COVID vaccines, the global market associated with the mRNA synthesis and mRNA manufacturing market is anticipated to witness a CAGR of -1.7% over the forecast period. The decline in the market size over the next decade is likely to be the result of a dip in the demand for COVID vaccines till 2035. Specifically, in terms of type of product, the market is anticipated to be driven by contract manufacturing of mRNA vaccines, followed by mRNA therapeutics. In addition to this, presently, close to 70% of the market is captured by players based in North America and Europe.
Majority of the companies offering mRNA synthesis services and mRNA vaccine manufacturing services are headquartered in North America and Europe. Consequently, presently, North America and Europe capture over 70% market share of the overall mRNA synthesis and mRNA manufacturing market. In recent years, demand for mRNA products, such as mRNA vaccines, in the North America region has witnessed a tremendous increase. However, in the coming years, owing to the anticipated mRNA-based drug approvals and growing need for GMP manufacturing of such products, Asia-Pacific region is likely to grow at a much faster rate as compared to other geographies.
Examples of key mRNA CDMO engaged in mRNA synthesis and mRNA manufacturing market (which have also been profiled in this market report; the complete list of players is available in the full report) include Aldevron, APExBIO, Biomay, BioNTech, CELLSCRIPT, CureVac, bioSYNTHESIS, eTheRNA, Eurogentec, Jena Biosciences, Moderna, New England Biolabs, Thermo Fisher Scientific and TriLink BioTechnologies. It is interesting to note that in October 2022, Thermo Fisher Scientific introduced a customized Dynabeads® solutions to support mRNA synthesis and purification for mRNA vaccine manufacturing and development. Such portfolio additions are expected to drive mRNA synthesis and mRNA manufacturing market growth during the forecast period.
Several recent developments have taken place in the field of mRNA synthesis and mRNA manufacturing market, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we have outlined in our analysis.
The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments as defined in the below table:
| Report Attribute | Details | |
| Base Year |
2023 |
|
| Forecast Period | 2023 – 2035 | |
| Market Size 2023 | $ 1.95 Billion | |
| CAGR | 1.7% | |
| Type of Product |
|
|
| Application Area |
|
|
| Therapeutic Areas |
|
|
| Key Geographical Regions |
|
|
| Key Companies Profiled |
(Full list of 80+ companies captured is available in the report) |
|
| PowerPoint Presentation (Complimentary) |
|
|
| Customization Scope |
|
|
| Excel Data Packs (Complimentary) |
|
|
The market report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry. Amongst other elements, the market research report includes:
 |
 |
 |
One of the key objectives of this mRNA synthesis and mRNA manufacturing market report was to estimate current market size and the future opportunity in the mRNA synthesis and mRNA manufacturing market over the forecast period. Based on multiple parameters, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the forecast period 2023-2035. In order to provide a detailed future outlook, year-wise projections of the current and future opportunity have been further segmented on the basis of relevant parameters, such as type of product (drug substances (APIs) and drug products (FDFs)), application areas (mRNA vaccines and mRNA-based therapeutics), target indications (infectious diseases, oncological disorders and other diseases), and key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. An Overview of mRNA
3.2. Structure of mRNA
3.3. Evolution of mRNA Vaccines
3.4. mRNA Manufacturing Process
3.4.1. Chemical Synthesis of mRNA
3.4.2. In vitro Synthesis of mRNA
3.5. Applications of Chemically / in vitro Synthesized mRNA
3.6. Challenges Associated with mRNA Synthesis
3.7. Commonly Outsourced Manufacturing Operations
3.8. Advantages of Outsourcing Manufacturing Operations
4. MARKET LANDSCAPE: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS
4.1. mRNA Custom Synthesis Service Providers: Overall Market Landscape
4.1.1. Analysis by Year of Establishment
4.1.2. Analysis by Company Size
4.1.3. Analysis by Location of Headquarters
4.1.4. Analysis by Company Size and Location of Headquarters
4.1.5. Analysis by Type of Service(s) Offered
4.1.6. Analysis by Input for Synthesis
4.1.7. Analysis by Structural Modification
4.1.8. Analysis by Type of Purification Method(s)
4.1.9. Analysis by Application Area(s)
4.1.10. Analysis by Scale of Operation
4.1.11. mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA Manufactured
4.1.12. mRNA Custom Synthesis Service Providers: Information on mRNA Synthesis / Manufacturing Capacity
5. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
5.1. Key Parameters and Scores
5.2. Methodology
5.3. Competitiveness Analysis: Small Companies
5.4. Competitiveness Analysis: Mid-Sized Companies
5.5. Competitiveness Analysis: Large Companies
6. MARKET LANDSCAPE: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS
6.1. mRNA Contract Manufacturing Service Providers: Overall Market Landscape
6.1.1. Analysis by Year of Establishment
6.1.2. Analysis by Company Size
6.1.3. Analysis by Location of Headquarters
6.1.4. Analysis by Company Size and Location of Headquarters
6.1.5. Analysis by Location of Manufacturing Facility
6.1.6. Analysis by Type of Product(s) Manufactured
6.1.7. Analysis by Type of Service(s) Offered
6.1.8. Analysis by Scale of Operation
7. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS (mRNA CDMO): COMPANY COMPETITIVENESS ANALYSIS
7.1. Methodology
7.2. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in North America
7.3. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Europe
7.4. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Asia-Pacific
8. MARKET LANDSCAPE: mRNA SYNTHESIS KIT PROVIDERS
8.1. mRNA Synthesis Kits: Overall Market Landscape
8.1.1. Analysis by Kit Components
8.1.2. Analysis by Type of Enzyme
8.1.3. Analysis by Type of Enzyme Mix Used
8.1.4. Analysis by mRNA Component Modified
8.1.5. Analysis by Yield per Reaction
8.1.6. Analysis by Number of Reactions
8.1.7. Analysis by Reaction Run-Time
8.1.8. Analysis by Price of Kits
8.1.9. Most Active Players: Analysis by Number of mRNA Synthesis Kits Offered
8.2. mRNA Synthesis Kits: Developer Landscape
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
9. mRNA SYNTHESIS KITS: PRODUCT COMPETITIVENESS ANALYSIS
9.1. Methodology
9.2. Product Competitiveness Analysis: mRNA Synthesis Kits
10. COMPANY PROFILES: mRNA SYNTHESIS AND MANUFACTURING SERVICE PROVIDERS
10.1. Aldevron
10.1.1. Company Overview
10.1.2. mRNA Synthesis Focused Services Portfolio
10.1.3. Recent Developments and Future Outlook
10.2. Biomay
10.2.1. Company Overview
10.2.2. mRNA Synthesis Focused Services Portfolio
10.2.3. Recent Developments and Future Outlook
10.3. bioSYNTHESIS
10.3.1. Company Overview
10.3.2. mRNA Synthesis Focused Services Portfolio
10.3.3. Future Outlook
10.4. eTheRNA
10.4.1. Company Overview
10.4.2. mRNA Synthesis Focused Services Portfolio
10.4.3. Recent Developments and Future Outlook
10.5. Eurogentec
10.5.1. Company Overview
10.5.2. mRNA Synthesis Focused Services Portfolio
10.5.3. Recent Developments and Future Outlook
10.6. TriLink BioTechnologies
10.6.1. Company Overview
10.6.2. mRNA Synthesis Focused Services Portfolio
10.6.3. Recent Developments and Future Outlook
11. COMPANY PROFILES: mRNA SYNTHESIS KIT PROVIDERS
11.1. APExBIO
11.1.1. Company Overview
11.1.2. mRNA Synthesis Kits Portfolio
11.2. CELLSCRIPT
11.2.1. Company Overview
11.2.2. mRNA Synthesis Kits Portfolio
11.3. Jena Biosciences
11.3.1. Company Overview
11.3.2. mRNA Synthesis Kits Portfolio
11.4. New England Biolabs
11.4.1. Company Overview
11.4.2. mRNA Synthesis Kits Portfolio
11.5. Thermo Fisher Scientific
11.5.1. Company Overview
11.5.2. mRNA Synthesis Kits Portfolio
12. CLINICAL TRIAL ANALYSIS
12.1. Methodology
12.2. mRNA-based Therapeutics / Vaccines: Clinical Trial Analysis
12.2.1. Analysis by Trial Registration Year
12.2.2 Analysis by Trial Status
12.2.3. Analysis by Trial Registration Year and Patients Enrolled
12.2.4. Analysis by Trial Registration Year and Trial Status
12.2.5. Analysis by Trial Phase
12.2.6. Analysis by Target Patient Population
12.2.7. Analysis by Therapeutic Area
12.2.8. Analysis by Type of Sponsor / Collaborator
12.2.9. Most Active Players: Analysis by Number of Trials
12.2.10. Analysis by Region
13. PARTNERSHIP AND COLLABORATIONS
13.1. Partnership Models
13.2. mRNA Synthesis and Manufacturing: Partnerships and Collaborations
13.1.1. Analysis by Year of Partnership
13.1.2. Analysis by Type of Partnership
13.1.3. Analysis by Year and Type of Partnership
13.1.4. Analysis by Type of Product
13.1.5. Analysis by Type of Partner
13.1.6. Most Active Players: Analysis by Number of Partnerships
13.1.7. Analysis by Local and International Agreements
13.1.8. Analysis by Intercontinental and Intracontinental Agreements
13.1.9. Analysis by Region
14. LIKELY PARTNERS ANALYSIS
14.1. Methodology
14.2. Likely Partners based in North America
14.2.1 Most Likely Partners based in North America
14.3. Likely Partners based
14.3.1 Most Likely Partners based in Europe
14.4. Likely Partners based in Asia Pacific and Rest of the World
14.4.1 Most Likely Partners based in Asia Pacific and Rest of the World
15. BIG PHARMA INITIATIVES
15.1. Methodology
15.2. Big Pharma Players: List of mRNA-based Therapeutics / Vaccines Focused Initiatives
15.3. Competitive Benchmarking of Big Pharma Players
15.3.1. Harvey Ball Analysis
15.3.2. Spider Web Analysis
16. MARKET FORECAST
16.1. Chapter Overview
16.2. Key Assumptions and Forecast Methodology
16.3. Global mRNA Synthesis and mRNA Manufacturing Market, 2022-2035
16.3.1. mRNA Synthesis and mRNA Manufacturing Market, 2022-2035: Distribution by Type of Product
16.3.1.1. mRNA Synthesis and mRNA Manufacturing Market for Drug Substances (APIs), 2022-2035
16.3.1.2. mRNA Synthesis and mRNA Manufacturing Market for Drug Products (FDFs), 2022-2035
16.3.2. mRNA Synthesis and Manufacturing Market, 2022-2035: Distribution by Application Area,
16.3.2.1. mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, 2022-2035
16.3.2.2. mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, 2022-2035
16.3.3. mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2022, 2025 and 2035
16.3.3.1. mRNA Synthesis and Manufacturing Market for Infectious Diseases, 2022-2035
16.3.3.1. mRNA Synthesis and Manufacturing Market for Oncological Disorders, 2022-2035
16.3.3.1. mRNA Synthesis and Manufacturing Market for Other Diseases, 2022-2035
16.3.4. mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2025 and 2035 (USD Billion)
16.3.4.1. mRNA Synthesis and Manufacturing Market in North America, 2022-2035
16.3.4.2. mRNA Synthesis and Manufacturing Market in Europe, 2022-2035
16.3.4.3. mRNA Synthesis and Manufacturing Market in Asia Pacific, 2022-2035
16.3.4.4. mRNA Synthesis and Manufacturing Market in Latin America, 2022-2035
16.3.4.5. mRNA Synthesis and Manufacturing Market in MENA, 2022-2035
16.3.4.6. mRNA Synthesis and Manufacturing Market in Rest of the World, 2022-2035
17. EXECUTIVE INSIGHTS
18. APPENDIX 1: TABULATED DATA
19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Overall Market Landscape of mRNA Custom Synthesis Service Providers
Figure 2.2 Executive Summary: Overall Market Landscape of mRNA Contract Manufacturing Service Providers
Figure 2.3 Executive Summary: Overall Market Landscape of mRNA Synthesis Kits
Figure 2.4 Executive Summary: Clinical Trial Analysis
Figure 2.5 Executive Summary: Partnership and Collaborations
Figure 2.6 Executive Summary: Likely Partners Analysis
Figure 2.7 Executive Summary: Big Pharma Initiatives
Figure 2.8 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Structure of mRNA
Figure 3.2 Evolution of mRNA Vaccines
Figure 3.3 Chemical Synthesis of mRNA
Figure 3.4 In vitro Synthesis of mRNA
Figure 4.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment
Figure 4.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size
Figure 4.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters
Figure 4.4 mRNA Custom Synthesis Service Providers: Distribution by Company Size and Location of Headquarters
Figure 4.5 mRNA Custom Synthesis Service Providers: Distribution by Type of Service(s) Offered
Figure 4.6 mRNA Custom Synthesis Service Providers: Distribution by Input for Synthesis
Figure 4.7 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification
Figure 4.8 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method(s)
Figure 4.9 mRNA Custom Synthesis Service Providers: Distribution by Application Area(s)
Figure 4.10 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation(s)
Figure 5.1 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Custom Synthesis Service Providers (Small Companies)
Figure 5.2 Company Competitiveness Analysis: Spider Web Analysis of mRNA Custom Synthesis Service Providers (Small Companies)
Figure 5.3 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Custom Synthesis Service Providers (Mid-Sized Companies)
Figure 5.4 Company Competitiveness Analysis: Spider Web Analysis of mRNA Custom Synthesis Service Providers (Mid-Sized Companies)
Figure 5.5 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Custom Synthesis Service Providers (Large Companies)
Figure 5.6 Company Competitiveness Analysis: Spider Web Analysis of mRNA Custom Synthesis Service Providers (Large Companies)
Figure 6.1 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment
Figure 6.2 mRNA Contract Manufacturing Service Providers: Distribution by Company Size
Figure 6.3 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters
Figure 6.4 mRNA Contract Manufacturing Service Providers: Distribution by Company Size and Location of Headquarters
Figure 6.5 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facility
Figure 6.6 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product(s) Manufactured
Figure 6.7 mRNA Contract Manufacturing Service Providers: Distribution by Type of Service(s) Offered
Figure 6.8 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation(s)
Figure 7.1 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Contract Manufacturing Service Providers based in North America
Figure 7.2 Company Competitiveness Analysis: Spider Web Analysis of mRNA Contract Manufacturing Service Providers based in North America
Figure 7.3 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Contract Manufacturing Service Providers based in Europe
Figure 7.4 Company Competitiveness Analysis: Spider Web Analysis of mRNA Contract Manufacturing Service Providers based in Europe
Figure 7.5 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Contract Manufacturing Service Providers based in Asia-Pacific
Figure 7.6 Company Competitiveness Analysis: Spider Web Analysis of mRNA Contract Manufacturing Service Providers based in Asia-Pacific
Figure 8.1 mRNA Synthesis Kits: Distribution by Kit Components
Figure 8.2 mRNA Synthesis Kits: Distribution by Type of Enzyme(s)
Figure 8.3 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used
Figure 8.4 mRNA Synthesis Kits: Distribution by mRNA Component Modified
Figure 8.5 mRNA Synthesis Kits: Distribution by Yield per Reaction
Figure 8.6 mRNA Synthesis Kits: Distribution by Number of Reactions
Figure 8.7 mRNA Synthesis Kits: Distribution by Reaction Run-Time
Figure 8.8 mRNA Synthesis Kits: Distribution by Price of Kits
Figure 8.9 Most Active Players: Distribution by Number of mRNA Synthesis Kits Offered
Figure 8.10 mRNA Synthesis Kit Providers: Distribution by Year of Establishment
Figure 8.11 mRNA Synthesis Kit Providers: Distribution by Company Size
Figure 8.12 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters
Figure 9.1 Product Competitiveness Analysis: Dot-Plot Representation of mRNA Synthesis Kits
Figure 9.2 Product Competitiveness Analysis: Dot-Plot Representation of Top mRNA Synthesis Kits
Figure 12.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 12.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 12.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Figure 12.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 12.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 12.6 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 12.7 Clinical Trial Analysis: Distribution by Therapeutic Area(s)
Figure 12.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 12.9 Most Active Players: Analysis by Number of Trials
Figure 12.10 Clinical Trial Analysis: Distribution by Region
Figure 13.1 Partnership and Collaborations: Distribution by Year of Partnership
Figure 13.2 Partnership and Collaborations: Distribution by Type of Partnership
Figure 13.3 Partnership and Collaborations: Distribution by Year and Type of Partnership
Figure 13.4 Partnership and Collaborations: Distribution by Type of Product(s)
Figure 13.5 Partnership and Collaborations: Distribution by Type of Partner
Figure 13.6 Most Active Players: Analysis by Number of Partnerships
Figure 13.7 Partnership and Collaborations: Distribution by Local and International Agreements
Figure 13.8 Partnership and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 13.9 Partnership and Collaborations: Distribution by Region
Figure 14.1 Likely Partners Analysis: Likely Partners based in North America
Figure 14.2 Likely Partners Analysis: Most Likely Partners based in North America
Figure 14.3 Likely Partners Analysis: Likely Partners based in Europe
Figure 14.4 Likely Partners Analysis: Most Likely Partners based in Europe
Figure 14.5 Likely Partners Analysis: Likely Partners based in Asia-Pacific and Rest of the World
Figure 14.6 Likely Partners Analysis: Most Likely Partners based in Asia-Pacific and Rest of the World
Figure 15.1 Competitive Benchmarking of Big Pharma Players: Harvey Ball Analysis
Figure 15.2 Competitive Benchmarking of Big Pharma Players: Spider Web Analysis
Figure 16.1 Global mRNA Synthesis and Manufacturing Market, 2022-2035
Figure 16.1 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product, 2022-2035 (USD Billion)
Figure 16.2 mRNA Synthesis and Manufacturing Market for Drug Substances (APIs), 2022-2035 (USD Billion)
Figure 16.3 mRNA Synthesis and Manufacturing Market for Drug Products (FDFs), 2022-2035 (USD Billion)
Figure 16.4 mRNA Synthesis and Manufacturing Market: Distribution by Application Area, 2022-2035 (USD Billion)
Figure 16.5 mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, 2022-2035 (USD Billion)
Figure 16.6 mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, 2022-2035 (USD Billion)
Figure 16.7 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2022, 2025 and 2035
Figure 16.8 mRNA Synthesis and Manufacturing Market for Infectious Diseases, 2022-2035 (USD Billion)
Figure 16.9 mRNA Synthesis and Manufacturing Market for Oncological Disorders, 2022-2035 (USD Billion)
Figure 16.10 mRNA Synthesis and Manufacturing Market for Other Diseases, 2022-2035 (USD Billion)
Figure 16.11 mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2022 and 2035 (USD Billion)
Figure 16.12 mRNA Synthesis and Manufacturing Market in North America, 2022-2035 (USD Billion)
Figure 16.13 mRNA Synthesis and Manufacturing Market in Europe, 2022-2035 (USD Billion)
Figure 16.14 mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2022-2035 (USD Billion)
Figure 16.15 mRNA Synthesis and Manufacturing Market in Latin America, 2022-2035 (USD Billion)
Figure 16.16 mRNA Synthesis and Manufacturing Market in MENA, 2022-2035 (USD Billion)
Figure 16.17 mRNA Synthesis and Manufacturing Market in Rest of the World, 2022-2035, USD Billion
Table 4.1 List of mRNA Custom Synthesis Service Providers
Table 4.2 mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA Manufactured
Table 4.3 mRNA Custom Synthesis Service Providers: Information on Synthesis / Manufacturing Capacity
Table 6.1 List of mRNA Contract Manufacturing Service Providers
Table 8.1 List of mRNA Synthesis Kits
Table 8.2 List of mRNA Synthesis Kits Providers
Table 10.1 Aldevron: mRNA Synthesis Focused Services Portfolio
Table 10.2 Aldevron: Recent Developments and Future Outlook
Table 10.3 Biomay: mRNA Synthesis Focused Services Portfolio
Table 10.4 Biomay: Recent Developments and Future Outlook
Table 10.5 bioSYNTHESIS: mRNA Synthesis Focused Services Portfolio
Table 10.6 bioSYNTHESIS: Recent Developments and Future Outlook
Table 10.7 eTheRNA: mRNA Synthesis Focused Services Portfolio
Table 10.8 eTheRNA: Recent Developments and Future Outlook
Table 10.9 Eurogentec: mRNA Synthesis Focused Services Portfolio
Table 10.10 Eurogentec: Recent Developments and Future Outlook
Table 10.11 TriLink BioTechnologies: mRNA Synthesis Focused Services Portfolio
Table 10.12 TriLink BioTechnologies: Recent Developments and Future Outlook
Table 11.1 APExBIO: mRNA Synthesis Kits Portfolio
Table 11.2 CELLSCRIPT: mRNA Synthesis Kits Portfolio
Table 11.3 Jena Biosciences: mRNA Synthesis Kits Portfolio
Table 11.4 New England Biolabs: mRNA Synthesis Kits Portfolio
Table 11.5 Thermo Fisher Scientific: mRNA Synthesis Kits Portfolio
Table 12.1 mRNA-based Therapeutics / Vaccines: List of Clinical Trials
Table 13.1 mRNA Synthesis and Manufacturing: List of Partnerships and Collaborations
Table 15.1 Big Pharma Players: List of mRNA-based Therapeutics / Vaccines Focused Initiatives
Table 16.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment
Table 16.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size
Table 16.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters
Table 16.4 mRNA Custom Synthesis Service Providers: Distribution by Company Size and Location of Headquarters
Table 16.5 mRNA Custom Synthesis Service Providers: Distribution by Type of Service(s) Offered
Table 16.6 mRNA Custom Synthesis Service Providers: Distribution by Input for Synthesis
Table 16.7 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification
Table 16.8 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method(s)
Table 16.9 mRNA Custom Synthesis Service Providers: Distribution by Application Area(s)
Table 16.10 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation(s)
Table 16.11 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment
Table 16.12 mRNA Contract Manufacturing Service Providers: Distribution by Company Size
Table 16.13 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters
Table 16.14 mRNA Contract Manufacturing Service Providers: Distribution by Company Size and Location of Headquarters
Table 16.15 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facility
Table 16.16 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product(s) Manufactured
Table 16.17 mRNA Contract Manufacturing Service Providers: Distribution by Type of Service(s) Offered
Table 16.18 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation(s)
Table 16.19 mRNA Synthesis Kits: Distribution by Kit Components
Table 16.20 mRNA Synthesis Kits: Distribution by Type of Enzyme(s)
Table 16.21 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used
Table 16.22 mRNA Synthesis Kits: Distribution by mRNA Component Modified
Table 16.23 mRNA Synthesis Kits: Distribution by Yield per Reaction
Table 16.24 mRNA Synthesis Kits: Distribution by Number of Reactions
Table 16.25 mRNA Synthesis Kits: Distribution by Reaction Run-Time
Table 16.26 mRNA Synthesis Kits: Distribution by Price of Kits
Table 16.27 Most Active Players: Distribution by Number of mRNA Synthesis Kits Offered
Table 16.28 mRNA Synthesis Kit Providers: Distribution by Year of Establishment
Table 16.29 mRNA Synthesis Kit Providers: Distribution by Company Size
Table 16.30 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters
Table 16.32 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 16.33 Clinical Trial Analysis: Distribution by Trial Status
Table 16.34 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Table 16.35 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 16.36 Clinical Trial Analysis: Distribution by Trial Phase
Table 16.37 Clinical Trial Analysis: Distribution by Target Patient Population
Table 16.38 Clinical Trial Analysis: Distribution by Therapeutic Area(s)
Table 16.39 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 16.40 Most Active Players: Distribution by Number of Trials
Table 16.41 Clinical Trial Analysis: Distribution by Region
Table 16.42 Partnership and Collaborations: Distribution by Year of Partnership
Table 16.43 Partnership and Collaborations: Distribution by Type of Partnership
Table 16.44 Partnership and Collaborations: Distribution by Year and Type of Partnership
Table 16.45 Partnership and Collaborations: Distribution by Type of Product(s)
Table 16.46 Partnership and Collaborations: Distribution by Type of Partner
Table 16.47 Most Active Players: Distribution by Number of Partnerships
Table 16.48 Partnership and Collaborations: Distribution by Local and International Agreements
Table 16.49 Partnership and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Table 16.50 Partnership and Collaborations: Distribution by Region
Table 16.51 Global mRNA Synthesis and Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.52 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product, 2022- 2035 (USD Billion)
Table 16.53 mRNA Synthesis and Manufacturing Market for Drug Substances (APIs) Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.54 mRNA Synthesis and Manufacturing Market for Drug Products (FDFs) Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.55 mRNA Synthesis and Manufacturing Market: Distribution by Application Area, 2022-2035 (USD Billion)
Table 16.56 mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.57 mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.58 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2022, 2025 and 2035
Table 16.59 mRNA Synthesis and Manufacturing Market for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.60 mRNA Synthesis and Manufacturing Market for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.61 mRNA Synthesis and Manufacturing Market for Other Diseases, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.62 mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2022 and 2035 (USD Billion)
Table 16.63 mRNA Synthesis and Manufacturing Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.64 mRNA Synthesis and Manufacturing Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.65 mRNA Synthesis and Manufacturing Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.66 mRNA Synthesis and Manufacturing Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.67 mRNA Synthesis and Manufacturing Market in MENA, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.68 mRNA Synthesis and Manufacturing Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
The following companies and organizations have been mentioned in the report:
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES